Literature DB >> 23639623

Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor.

K E Andreassen1, W Kristiansen, R Karlsson, E L Aschim, O Dahl, S D Fosså, H-O Adami, F Wiklund, T B Haugen, T Grotmol.   

Abstract

STUDY QUESTION: Is there an association between testicular germ cell tumor (TGCT) and genetic polymorphisms in AKT1, PTEN and the 8q24 locus? SUMMARY ANSWER: Our findings suggest that genetic variation in PTEN may influence the risk of TGCT. WHAT IS KNOWN ALREADY: There is strong evidence that genetic variation influences the risk of TGCT. The oncogene, AKT1, the tumor suppressor gene, PTEN and the chromosome 8q24 locus play important roles in cancer development in general. STUDY DESIGN, SIZE, DURATION: We have conducted a population-based Norwegian-Swedish case-parent study, based on cases diagnosed in 1990-2008, including 831 triads (TGCT case and both parents), 474 dyads (TGCT case and one parent) and 712 singletons (only the TGCT case). In addition we expanded the study to include 3922 unrelated male controls from the TwinGene project. PARTICIPANTS/MATERIALS, SETTING,
METHODS: We genotyped 26 single nucleotide polymorphisms (SNPs) in AKT1, PTEN and the 8q24 locus. First, triads and dyads were included in a likelihood-based association test. To increase the statistical power, case singletons and controls from the TwinGene project were included in a single test for association. We examined if the allelic effect on TGCT risk differed by histological subgroup, country of origin or parent of origin. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated with Bonferroni correction (P bonf) for multiple testing. MAIN RESULTS AND THE ROLE OF CHANCE: In the case-parent analyses, none of the 26 SNPs were significantly associated with TGCT. Of the 23 SNPs investigated in the combined study, one SNP in PTEN (rs11202586) remained associated with TGCT risk after adjusting for multiple testing (OR = 1.16, 95% CI = 1.06-1.28, P bonf = 0.040). We found no difference in risk according to histological subgroup, parent of origin or between countries. LIMITATIONS, REASONS FOR CAUTION: Our study is strengthened by the population-based design and large sample size, which gives high power to detect risk alleles. The reported association was not highly significant, and although it was based on an a priori hypothesis of this tumor suppressor gene being implicated in the etiology of TGCT, replication studies, as well as functional studies of this polymorphism, are warranted. WIDER IMPLICATIONS OF THE
FINDINGS: We report, to our knowledge, a novel association between TGCT and a marker in the tumor suppressor gene PTEN. Previous studies have linked PTEN to TGCT etiology, and there is also a link between PTEN and KITLG, which contains TGCT susceptibility loci revealed through recent genome-wide studies.

Entities:  

Keywords:  8q24; Akt1; Pten; single nucleotide polymorphism; testicular cancer

Mesh:

Substances:

Year:  2013        PMID: 23639623     DOI: 10.1093/humrep/det127

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

1.  Misexpression of cyclin D1 in embryonic germ cells promotes testicular teratoma initiation.

Authors:  Denise G Lanza; Emily P Dawson; Priya Rao; Jason D Heaney
Journal:  Cell Cycle       Date:  2016-02-22       Impact factor: 4.534

Review 2.  Molecular biology of testicular germ cell tumors.

Authors:  R Gonzalez-Exposito; M Merino; C Aguayo
Journal:  Clin Transl Oncol       Date:  2015-10-19       Impact factor: 3.405

Review 3.  Reprogramming of germ cells into pluripotency.

Authors:  Yoichi Sekita; Toshinobu Nakamura; Tohru Kimura
Journal:  World J Stem Cells       Date:  2016-08-26       Impact factor: 5.326

4.  Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway.

Authors:  Nian-Qin Yang; Xiao-Jin Luo; Jian Zhang; Guo-Min Wang; Jian-Ming Guo
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Authors:  Kenneth S Chen; Nicholas J Fustino; Abhay A Shukla; Emily K Stroup; Albert Budhipramono; Christina Ateek; Sarai H Stuart; Kiyoshi Yamaguchi; Payal Kapur; A Lindsay Frazier; Lawrence Lum; Leendert H J Looijenga; Theodore W Laetsch; Dinesh Rakheja; James F Amatruda
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

6.  Association of phosphatase and tension homologue deleted on chromosome ten polymorphism rs1903858, but not serum levels with the risk of non-small-cell lung cancer: A case-control study.

Authors:  Zhen Liang; Yuzhu Tang; Hao Li; Youjun Xie; Lingling Zhan
Journal:  J Clin Lab Anal       Date:  2020-06-15       Impact factor: 2.352

7.  Single nucleotide polymorphisms rs701848 and rs2735343 in PTEN increases cancer risks in an Asian population.

Authors:  Dan-Dan Song; Qian Zhang; Jing-Hua Li; Rui-Min Hao; Ying Ma; Ping-Yu Wang; Shu-Yang Xie
Journal:  Oncotarget       Date:  2017-10-24

8.  Subfertility and Risk of Testicular Cancer in the EPSAM Case-Control Study.

Authors:  Chiara Grasso; Daniela Zugna; Valentina Fiano; Nena Robles Rodriguez; Milena Maule; Anna Gillio-Tos; Libero Ciuffreda; Patrizia Lista; Nereo Segnan; Franco Merletti; Lorenzo Richiardi
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

9.  Seminoma and embryonal carcinoma footprints identified by analysis of integrated genome-wide epigenetic and expression profiles of germ cell cancer cell lines.

Authors:  Yvonne G van der Zwan; Martin A Rijlaarsdam; Fernando J Rossello; Amanda J Notini; Suzan de Boer; D Neil Watkins; Ad J M Gillis; Lambert C J Dorssers; Stefan J White; Leendert H J Looijenga
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

Review 10.  Exploring the molecular aspects associated with testicular germ cell tumors: a review.

Authors:  Gaetano Facchini; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Gelsomina Iovane; Giovanni Grimaldi; Raffaele Piscitelli; Paolo Muto; Gerardo Botti; Sisto Perdonà; Bianca Maria Veneziani; Massimiliano Berretta; Micaela Montanari
Journal:  Oncotarget       Date:  2017-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.